摘要
[目的]探讨复方黄柏液灌肠联合美沙拉嗪对溃疡性结肠炎(UC)患者黏附因子的影响,并进行疗效分析。[方法]选择2015-03-2017-08期间收治的90例UC患者,依据随机数字表法分为研究组与对照组,各45例。对照组采用口服美沙拉嗪1 g/次、4次/d治疗,研究组采用复方黄柏液灌肠联合口服美沙拉嗪治疗,剂量同上。疗程均为3个月。比较2组患者治疗前后的症状积分、肠镜积分、肠道菌群数量及黏附因子的变化,分析2组患者的疗效。[结果]研究组与对照组患者治疗前症状积分、肠镜积分、肠道菌群数量及黏附因子比较均差异无统计学意义(P>0.05);治疗后,2组患者腹痛、腹泻、脓血便症状积分及肠镜积分均降低,研究组患者各项积分均显著低于对照组(P<0.05)。2组患者经治疗后肠球菌数量、ICAM-1及VCAM-1水平显著降低,双歧杆菌与乳酸杆菌数量显著升高(均P<0.05);且研究组患者肠球菌数量、ICAM-1及VCAM-1水平显著低于对照组,双歧杆菌与乳酸杆菌的数量显著高于对照组(均P<0.05)。研究组有效率显著高于对照组(93.33%∶75.56%,P<0.05)。[结论]复方黄柏液灌肠联合美沙拉嗪治疗UC患者,可显著改善其临床症状及菌群紊乱,下调黏附因子的表达,治疗效果较好。
[Objective]To investigate the effect of compound Huangbai liquid enema combined with mesalazine on adhesion factor in patients with ulcerative colitis,and to analyze the effect.[Methods]Ninety patients with UC who were admitted to Shunyi District Hospital of Beijing from March 2015 to August 2017 were randomly divided into control group and study group,45 cases in each group.The control group was treated with oral mesalazine,and the study group was treated with compound cork liquid enema combined with mesalazine.The symptoms score,colonoscopy scores,intestinal flora number and adhesion factor were compared between the two groups before and after treatment.The efficacy of the two groups of patients after treatment was analyzed.[Results]There were no significant differences in pre-treatment symptoms score,colonoscopy scores,intestinal flora numbers and adhesion factors between the two groups(P>0.05).After treatment,the abdominal pain,diarrhea,pus and bloody stool score and colonoscopy score were decreased in both groups(P<0.05).And the above score of the study group were significantly lower than the control group(P<0.05).The number of enterococci,ICAM-1 and VCAM-1 levels in the two groups were significantly decreased after treatment,and the number of bifidobacteria and lactobacilli was significantly increased(P<0.05).The number of enterococci,ICAM-1 and VCAM-1 in the study group was significantly lower than that in the control group,and the number of bifidobacteria and lactobacilli was significantly higher than that in the control group(all P<0.05).The effective rate of the study group was 93.33%,which was significantly higher than that of the control group(75.56%),P<0.05.[Conclusion]Compound Huangbai liquid Enema combined with Mesalazin tablets treat patients with ulcerative colitis,which can significantly improve clinical symptoms and flora disorder,down-regulate the expression of adhesion factors,and the therapeutic effect is better.
作者
张烨
李春涛
鲁蕾
刘亮
ZHANG Ye;LI Chun-tao;LU Lei;LIU Liang(Department of Gastroenterology,Shunyi District Hospital of Beijing,101300 Beijing,China)
出处
《临床消化病杂志》
2019年第5期312-315,共4页
Chinese Journal of Clinical Gastroenterology
